PDCD1 and non-small cell lung carcinoma: From the initial approval of nivolumab (PD-1 inhibitor) in 2015 for patients with metastatic NSCLC and progression after platinum-based chemotherapy, these agents are now approved as frontline treatment of metastatic NSCLC with or without chemotherapy, as consolidation therapy after concurrent chemotherapy and radiation in locally advanced NSCLC, and in the adjuvant setting after surgical resection and adjuvant chemotherapy.